CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r (400/50mg).
This prescribing memo has been developed to assist healthcare workers with prescribing DRV/r for use after dolutegravir (DTG) failure or intolerability in patients who have not previously failed a PI (or in patients confirmed to have no DRV resistance-associated mutations following prior PI use) or those interested in switching to DRV/r given improved tolerability and efficacy over other PIs.
This can be a standalone guide or incorporated into other training materials. This resources is being shared in PPT format so that it can easily be customized to fit an individual country’s local context.